NeuroDerm enrolls patients in second ND0612 Phase II clinical trial for treatment of Parkinson's disease | #ALS AWARENESS #LouGehrigsDisease #PARKINSONS | Scoop.it
NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease.